-
Product Insights
NewMitochondrial Myopathy – Drugs In Development, 2024
Empower your strategies with our Mitochondrial Myopathy – Drugs In Development, 2024 report and make more profitable business decisions. Mitochondria are known as "the powerhouse of the cell," but when defects occur they give rise to mitochondrial diseases. Mitochondrial diseases affecting the muscles are known as mitochondrial myopathies. These can occur because of fetal gene mutations in the mitochondria, resulting in childhood myopathies. Symptoms include fatigue, muscle weakness, stunted growth, and exercise intolerance, as production of adenosine triphosphate (ATP), a cellular...
-
Product Insights
IgA Nephropathy (Berger’s Disease) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
IgA Nephropathy Clinical Trial Report Overview A total of 298 IgA Nephropathy clinical trials were conducted as of January 2024. The IgA Nephropathy clinical trial report provides a comprehensive understanding of the IgA Nephropathy clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe...
-
Product Insights
NewAlport Syndrome – Drugs In Development, 2024
Empower your strategies with our Alport Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Alport syndrome is a genetic disorder characterized by glomerulonephritis, end-stage kidney disease, and hearing loss. It is caused by an inherited defect in type IV collagen—a structural material that is needed for the normal function of different parts of the body. Since type IV collagen is found in the ears, eyes, and kidneys, this explains why Alport syndrome affects different seemingly unrelated...
-
Product Insights
NewVasculitis – Drugs In Development, 2024
Empower your strategies with our Vasculitis – Drugs In Development, 2024 report and make more profitable business decisions. Vasculitis is a term that refers to a group of diseases that cause inflammation of the blood vessels, affecting both arteries and veins. Vasculitis can have various causes, such as genetic factors, infections, immune system disorders, blood cancers, or reactions to certain drugs. Vasculitis can affect different parts of the body, such as the skin, muscles, joints, nerves, lungs, heart, digestive system, kidneys,...
-
Product Insights
NewFocal Segmental Glomerulosclerosis (FSGS) – Drugs In Development, 2024
Empower your strategies with our Focal Segmental Glomerulosclerosis (FSGS) – Drugs In Development, 2024 report and make more profitable business decisions. Focal segmental glomerulosclerosis (FSGS) is a rare kidney disease that causes scarring of the glomeruli, the tiny filters that remove waste from the blood. The scarring affects only some parts of some glomeruli, hence the name "focal segmental". FSGS can lead to protein loss in the urine, swelling in the body, high cholesterol, and kidney failure. FSGS can have different...
-
Product Insights
NewAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) – Drugs In Development, 2024
Empower your strategies with our Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) – Drugs In Development, 2024 report and make more profitable business decisions. Anti-neutrophil cytoplasmic antibody-associated (ANCA) vasculitis is a group of autoimmune diseases that cause inflammation and damage to small blood vessels. It is triggered by autoantibodies called ANCAs that target and attack neutrophils, a type of white blood cell. ANCA vasculitis can affect different organs or parts of the body, such as the skin, kidney, or lung. The symptoms,...
-
Product Insights
NewIgA Nephropathy (Berger’s Disease) – Drugs In Development, 2024
Empower your strategies with our IgA Nephropathy (Berger's Disease) – Drugs In Development, 2024 report and make more profitable business decisions. IgA nephropathy, also known as Berger's disease, is a kidney disorder characterized by the buildup of the antibody immunoglobulin A (IgA) in the small blood vessels (glomeruli) within the kidneys. This condition can lead to inflammation, damage, and scarring of the kidneys, affecting their ability to filter waste and excess fluids from the blood. The exact cause of IgA nephropathy...
-
Product Insights
NewGlomerulonephritis – Drugs In Development, 2024
Empower your strategies with our Glomerulonephritis – Drugs In Development, 2024 report and make more profitable business decisions. Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat (strep throat), immune diseases such as lupus, type 1 and type 2 diabetes, and viral infections such as HIV, hepatitis B virus, and hepatitis C virus. Risk factors include family...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HFB-200603 in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HFB-200603 in Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HFB-200603 in Renal Cell Carcinoma Drug Details: HFB-200603 is under...